From: Board of Pharmacy <pharmacy.subscriberlist@DCA.CA.GOV>
Sent: Tuesday, June 06, 2017 9:39 AM
To: PHARM-GENERAL@DCALISTS.CA.GOV
Cc: Pharmacy_Subscriberlist@DCA
Subject: Rercall notice - Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is initiating a recall of one lot of Eliquis 5 mg tablets, HN0063. This recall is being conducted to the retail/dispensing level with the knowledge of the US Food and Drug Administration (FDA), and is limited to this specific Eliquis 5 mg tablet lot, HN0063.

This recall is being conducted based on the Company's investigation of one field complaint of a single Eliquis 5 mg strength bottle containing lower-strength 2.5 mg tablets instead of the labeled 5 mg tablets.

Please immediately check your inventory, quarantine, discontinue distribution of the affected product, and contact your wholesaler for directions.

NDC	Description	Lot Number	Expiration
0003-0894-21	ELIQUIS TAB 5 MG (1BTLX60) US	HN0063	SEP 2019